UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number 000-19125 Ionis Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q2 2022 Earnings Conference Call August 9, 2022 11:30 AM ET Company Participants Brett Monia - Chief Executive Officer Beth Hougen - Chief Financial Officer Richard Geary - Executive Vice President of Development Eric Swayze - Executive Vice President of Research Eugene Schneider - Chief Clinical Development Officer Onaiza Cadoret - Chief Global Product Strategy & Operations Officer Conference Call Participants Yanan Zhu - Wells Fargo Jessica Fye - JPMorgan Do Kim - ...

IONIS | --- | --- | --- | --- | --- | |----------------|-------|-------|-------|-------| | | | | | | | August 9, 2022 | | | | | | Nasdaq: IONS | | | | | | | | | | | On Today's Earnings Call 2 Brett Monia, Ph.D. Chief Executive Officer Beth Hougen Chief Financial Officer Richard Geary, Ph.D. Executive Vice President, Development Eric Swayze, Ph.D. Executive Vice President, Research Eugene Schneider, M.D. Executive Vice President, Chief Clinical Development Officer Onaiza Cadoret Executive Vice President, Chi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Delaware 33-0336973 2855 Gazelle Court, Carlsbad, California 92010 (Address of Principal Executive Offices) (Zip Code) 760-931-9200 For the Quarterly Period Ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file nu ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q1 2022 Earnings Conference Call May 4, 2022 11:30 AM ET Company Participants Brett Monia - Founder, CEO & Director Elizabeth Hougen - EVP, Finance & CFO Eugene Schneider - EVP & Chief Clinical Development Officer Eric Swayze - EVP, Research Onaiza Cadoret - EVP and Chief Product Strategy & Operations Officer Conference Call Participants Yanan Zhu - Wells Fargo Securities Brendan Smith - Cowen and Company Luca Issi - RBC Capital Markets Jessica Fye - JPMorgan Chase ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number 000-19125 Ionis Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of i ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q4 2021 Results Earnings Conference Call February 24, 2022 11:30 AM ET Company Participants Jennifer Capuzelo - Director of Investor Relation Brett Monia - Founder & CEO Beth Hougen - Chief Financial Officer Richard Geary - Executive Vice President & Chief Development Officer Eric Swayze - Executive Vice President of Research Onaiza Cadoret-Manier - Executive Vice President & Chief Product Strategy & Operations Officer Conference Call Participants Gary Nachman - BMO ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number 000-19125 Ionis Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 33-0336973 (State or other ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q3 2021 Earnings Conference Call November 3, 2021 11:30 AM ET Company Participants Jennifer Capuzela - Director of Investor Relation Brett Monia - Founder, CEO & Director Beth Hougen - Chief Financial Officer Richard Geary - EVP & Chief Development Officer Onaiza Cadoret-Manier - EVP and Chief Corporate Development & Commercial Officer Eric Swayze - EVP of Research Conference Call Participants Yale Jen - Laidlaw & Co Chi Meng Fong - BofA Securities Yanan Zhu - Wells ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number 000-19125 Ionis Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 33-0336973 (State or ...